Phase 1 dose escalation (DEs) & expansion (DEx) study to evaluate the safety & efficacy of IDE397 plus sacituzumab-govitecan in patients with advanced urothelial carcinoma (UC) with MTAP deletion (MTAPdel).

Charlene Mantia

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Chang Gon Kim

Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

Jordi Rodon Ahnert

The University of Texas MD Anderson Cancer Center, Houston, TX

Omar Alhalabi

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Alexander Z Wei

Columbia University Irving Medical Center, New York, NY

Mark N. Stein

Columbia University Medical Center, New York, NY

Melissa Lynne Johnson

Sarah Cannon Research Institute, Nashville, TN

Benjamin Garmezy

Sarah Cannon Research Institute, Nashville, TN

Alok Tewari

Dana-Farber Cancer Institute, Boston, MA

Sid Devarakonda

Swedish Cancer Institute, Seattle, WA

Abhishek Tripathi

Department of Medical Oncology and Therapeutics Research City of Hope Comprehensive Cancer Center Duarte California USA

Benedito A. Carneiro

Legorreta Cancer Center at Brown University, Providence, RI

Inkeun Park

Asan Medical Center, Seoul, South Korea

Valentina Boni

NEXT Madrid, Universitary Hospital Quirónsalud Madrid, Madrid, Spain

Emily Liu

University of Chicago

Jasgit C. Sachdev

IDEAYA Biosciences, San Francisco, CA

Mick O'Quigley

Ideaya Biosciences, South San Francisco, CA

Claire Neilan

IDEAYA Biosciences, South San Francisco, CA

Darrin M. Beaupre

IDEAYA Biosciences, San Francisco, CA

Hye Ryun Kim

Division of Medical Oncology, Department of Internal Medicine, Yonsei University Cancer Center, Yonsei University College of Medicine, Seoul, South Korea